Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment

Leukemia volume 30, pages 243–247 (2016)Cite this article

Subjects

Patients who receive cytotoxic chemotherapy and/or radiation therapy for breast cancer are at risk for developing therapy-related myeloid neoplasms (t-MN), which include acute myeloid leukemia (t-AML), myelodysplastic syndrome (t-MDS) and myelodysplastic/myeloproliferative neoplasms (t-MDS/MPN).1

Indeed, breast cancer ranks among the most common malignant solid tumors in patients who develop t-MN in population-based analyses.2, 3 Although several studies have addressed the impact of chemotherapy and radiation therapy on t-MN development in patients with breast cancer, prognostic modeling to assess the risk of t-MN in patients with breast cancer treated with modern approaches has been hampered by a lack of systematic analyses that simultaneously take into consideration demographics and patient comorbidities, primary malignancy factors, including therapy with novel antiestrogen agents, as well as the characteristics of t-MDS/MPN. To bridge this knowledge gap, we conducted a comprehensive single-institution case–control study with institutional review board approval to assess the demographic, biological and therapeutic features of patients with breast cancer who subsequently developed t-MN.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I et al. Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008; pp 214–217.

    Google Scholar 

  2. Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013; 121: 2996–3004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ramadan SM, Suciu S, Stevens-Kroef MJPL, Willemze R, Amadori S, Witte Td et al. Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON Leukemia Group Trials. Blood 2013; 122: 829a.

    Google Scholar 

  4. Khoury JD, Sen F, Abruzzo LV, Hayes K, Glassman A, Medeiros LJ . Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol 2003; 34: 1022–1029.

    Article  CAS  PubMed  Google Scholar 

  5. Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K et al. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol 2013; 24: 2515–2521.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E et al. Acute myeloid leukemia. J Natl Compr Cancer Netw 2012; 10: 984–1021.

    Article  CAS  Google Scholar 

  7. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rosato V, Bosetti C, Talamini R, Levi F, Montella M, Giacosa A et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011; 22: 2687–2692.

    Article  CAS  PubMed  Google Scholar 

  9. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218–1226.

    Article  CAS  PubMed  Google Scholar 

  10. Balkwill F, Charles KA, Mantovani A . Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211–217.

    Article  CAS  PubMed  Google Scholar 

  11. Kaye JA, Meier CR, Walker AM, Jick H . Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer 2002; 86: 1436–1439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Liao S, Li J, Wei W, Wang L, Zhang Y, Li J et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev 2011; 12: 1061–1065.

    PubMed  Google Scholar 

  13. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 2005; 103: 1122–1128.

    Article  CAS  PubMed  Google Scholar 

  14. Armand P, Kim HT, Mayer E, Cutler CS, Ho VT, Koreth J et al. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant 2010; 45: 1611–1617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2014; 518: 552–555.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Cancer Institute (CA016672, MD Anderson Cancer Center Support Grant); the Slovak Grant Agency (VEGA 1/0724/11 to MM); and the Slovak Research and Development Agency (APVV-0016-11 to KS and MM). We thank Sherry Pierce (Leukemia) and Limin Hsu (Breast Medical Oncology) for assistance with database queries. We also thank Leiloni Gilbert for administrative support.

Author Contributions

Khoury: Conception and design of study, data analysis, and manuscript preparation. Sevcikova and Zuo: Data collection, data analysis, and manuscript preparation. Zuo: Statistical analysis. Garcia-Manero, Alvarez, Kantarjian, Mego, Albarracin, Tang, Strom, Medeiros, Hortobagyi, and Reuben: Data analysis and manuscript preparation. All the authors read and approved the final manuscript.

Author information

Author notes

  1. R H Alvarez

    Present address: 8Present address: Cancer Treatment Centers of America, Atlanta, GA, USA.,

Authors and Affiliations

  1. Department of Medical Oncology, Comenius University, Faculty of Medicine, St Elizabeth Cancer Institute, Bratislava, Slovak Republic

    K Sevcikova

  2. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Z Zhuang, G Tang, L J Medeiros, J M Reuben & J D Khoury

  3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    G Garcia-Manero & H M Kantarjian

  4. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    R H Alvarez & G N Hortobagyi

  5. Second Department of Medical Oncology, Comenius University, Faculty of Medicine, National Cancer Institute, Bratislava, Slovak Republic

    M Mego

  6. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    C Albarracin

  7. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    S S Strom

Authors
  1. K Sevcikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Garcia-Manero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R H Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H M Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Mego
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Albarracin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S S Strom
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L J Medeiros
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G N Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J M Reuben
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J D Khoury
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J D Khoury.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

This work has been presented at the 2014 American Society for Hematology annual meeting and the Society for Hematology and Oncology annual meeting.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sevcikova, K., Zhuang, Z., Garcia-Manero, G. et al. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia 30, 243–247 (2016). https://doi.org/10.1038/leu.2015.122

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.122

Search

Advanced search

Quick links